

Information Sheet

Semi Polar Metabolites QC Mix

Catalog Number SBR00052

Product Description

Metabolomics is the profiling study of small molecules (metabolites) from biochemical processes and pathways,^{1,2} which are mostly characterized from samples of stool,³ serum/plasma,⁴ urine,⁵ cerebrospinal fluid,⁶ and saliva.⁷ Metabolomics deals with diverse areas like microbiome,⁸ nutrition⁹, diseases¹⁰ and agriculture¹¹, where metabolites are analyzed by two main approaches: targeted and untargeted metabolomics. Targeted metabolomics^{12,13} is the analysis of known specific chemical group such as: short chain fatty acids,¹⁶ bile acids, lipids,¹⁷ and amino acids.¹⁸ Untargeted metabolomics^{14,15} is the analysis of all unknown chemical compounds in a single sample.

Liquid chromatography-mass spectrometry (LC-MS) is the main method for metabolite profiling in metabolomics analysis.^{19,20}

In order to assess any variations in the LC-MS-based metabolomics analysis data, it is recommended to add an additional known QC (quality control) sample at the beginning of every analytical experiment batch with additional QC sample injections after every 4-10 unknown samples injections into the workflow steps.^{19,21,22} The known QC sample evaluates any drifting phenomenon like intensity values, ion suppression or other changes in the retention time of the materials peaks in the LC-MS data.

The Semi Polar Metabolites QC Mix is a ready-to-use solution for mass spectroscopy workflows. By utilizing the QC mix, the user will be able to assess drifting and ion suppression phenomena. The Semi Polar Metabolites QC Mix is comprised of 9 components (see Table 1), containing bile acids, aromatic carboxylic acids, and nucleosides.

Components

Table 1.

Components in the Semi Polar Metabolites QC Mix

No.	Metabolite name	Empirical Formula	Exact mass	Concentration (µg/mL)	Concentration (µM)
1	Uridine	C ₉ H ₁₂ N ₂ O ₆	244.0695	10	40.95
2	Adenosine	C ₁₀ H ₁₃ N ₅ O ₄	267.0967	5	18.71
3	Guanosine	C ₁₀ H ₁₃ N ₅ O ₅	283.0916	5	17.65
4	4-Hydroxybenzoic acid	C ₇ H ₆ O ₃	138.0316	10	72.40
5	Vanillic acid	C ₈ H ₈ O ₄	168.0422	20	118.94
6	Melatonin	C ₁₃ H ₁₆ N ₂ O ₂	232.1211	2.5	10.76
7	Taurocholic acid	C ₂₆ H ₄₅ NO ₇ S	515.2916	2	3.72
8	Cholic acid	C ₂₄ H ₄₀ O ₅	408.2875	2.5	5.81
9	Hyodeoxycholic acid	C ₂₄ H ₄₀ O ₄	392.2926	2.5	6.37

Equipment Required but Not Provided

- ACQUITY UPLC HSS T3 1.8 μm , 100 \AA
2.1 \times 150 mm, Waters Catalog
Number 186003540

Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Storage/Stability

The product is shipped at ambient temperature. Store at +2 $^{\circ}\text{C}$ to +8 $^{\circ}\text{C}$ upon receipt.

Preparation Instructions

The Semi Polar Metabolites QC Mix is a ready-to-use solution supplied in a crimp top (Silicone/PTFE liner) amber vial.

Procedure

Experimental procedures provided here are an example of how to use the products. The results may vary under different experimental parameters.

Mass Spectrometry Conditions:

Instrument: Bruker™ Q-ToF Impact II
Source Type: ESI

Method A:

Ion Polarity: Negative
Capillary: 5500 V
Nebulizer: 2.2 Bar
Dry gas temperature: 200 $^{\circ}\text{C}$
Dry gas: 8L/min

Method B:

Ion Polarity: Positive
Capillary: 4500 V
Nebulizer: 2.2 Bar
Dry gas temperature: 200 $^{\circ}\text{C}$
Dry gas: 8L/min

LC conditions:

Column: ACQUITY UPLC HSS T3 1.8 μm
2.1 \times 150 mm
Column oven temperature: 35 $^{\circ}\text{C}$
Flow rate: 0.4 ml/min
Injection volume: 1 μL
Gradient: See Table 2

Table 2.

Time (min)	Acetonitrile [%]	Water + 0.1% Formic acid [%]
0	2	98
2	2	98
17	70	30
19	2	98
26	2	98

Figure 1.

Method A: BPC chromatogram of MS ESI⁻ of Semi Polar Metabolites QC Mix and table of peak assignments (Table 3). Note: Adenosine is not detected under negative ion polarity.





Table 3.

Peak no.	Metabolite name	Rt (min)
1	Uridine	2.7
2	Guanosine	4.7
3	4-Hydroxybenzoic acid	8.8
4	Vanillic acid	9.5
5	Melatonin	11.9
6	Taurocholic acid	14.5
7	Cholic acid	16.8
8	Hyodeoxycholic acid	17.1

Figure 2.

Method B: BPC chromatogram of MS ESI⁺ of Semi Polar Metabolites QC Mix and table of peak assignments (Table 4).

**Table 4.**

Peak no.	Metabolite name	Rt (min)
1	Uridine	2.7
2	Adenosine	4.0
3	Guanosine	4.7
4	4-Hydroxybenzoic acid	8.8
5	Vanillic acid	9.5
6	Melatonin	11.9
7	Taurocholic acid	14.5
8	Cholic acid	16.8
9	Hyodeoxycholic acid	17.1

References

1. Oliver, S.G., *et al.*, Systematic functional analysis of the yeast genome. *Trends Biotechnol.*, **16(9)**, 373-378 (1998).
2. Cho, K., *et al.*, After the feature presentation: technologies bridging untargeted metabolomics and biology. *Curr. Opin. Biotechnol.*, **28**, 143-148 (2014).
3. Karu, N., *et al.*, A review on human fecal metabolomics: Methods, applications and the human fecal metabolome database. *Anal. Chim. Acta*, **1030**, 1-24 (2018).
4. Psychogios, N., *et al.*, The human serum metabolome. *PLoS one*, **6(2)**, e16957 (2011).
5. Bouatra, S., *et al.*, The human urine metabolome. *PLoS one*, **8(9)**, e73076 (2013).
6. Wishart, D.S., *et al.*, The human cerebrospinal fluid metabolome. *J. Chromatog.*, **871(2)**, 164-173 (2008).
7. Dame, Z.T., *et al.*, The human saliva metabolome. *Metabolomics*, **11(6)**, 1864-1883 (2015).
8. Bauermeister, A., *et al.*, Mass spectrometry-based metabolomics in microbiome investigations. *Nat. Rev. Microbio.*, **20(3)**, 143-160 (2021).
9. Tebani, A., and Bekri, S., Paving the way to precision nutrition through metabolomics. *Front. Nutr.*, **6**, 41 (2019).
10. Tounta, V., *et al.*, Metabolomics in infectious diseases and drug discovery. *Mol. Omics*, **17(3)**, 376-393 (2021).
11. Hong, J., *et al.*, Plant metabolomics: an indispensable system biology tool for plant science. *Int. J. Mol. Sciences*, **17(6)**, 767 (2016).
12. Nikolskiy, I., *et al.*, Discriminating precursors of common fragments for large-scale metabolite profiling by triple quadrupole mass spectrometry. *Bioinformatics*, **31(12)**, 2017-2023 (2015).
13. Patti, G.J., *et al.*, Metabolomics: the apogee of the omics trilogy. *Nat. Rev. Mol. Cell Biol.*, **13(4)**, 263-269 (2012).
14. Roberts, L.D., *et al.*, Targeted metabolomics. *Curr. Protoc. Mol. Biol.*, **98(1)**, 30.2 (2012).
15. Zheng, X., *et al.*, A targeted metabolomic protocol for short-chain fatty acids and branched-chain amino acids. *Metabolomics*, **9(4)**, 818-827 (2013).
16. Schrimpe-Rutledge, A.C., *et al.*, Untargeted metabolomics strategies—challenges and emerging directions. *J. Am. Soc. Mass Spectrom.*, **27(12)**, 1897-1905 (2016).
17. Griffiths, W.J., *et al.*, Targeted metabolomics for biomarker discovery. *Angew. Chem. Int. Ed. Engl.*, **49(32)**, 5426-5445 (2010).
18. Klepacki, J., *et al.*, (2016). Amino acids in a targeted versus a non-targeted metabolomics LC-MS/MS assay. Are the results consistent? *Clin. Biochem.*, **49(13-14)**, 955-961 (2016).
19. Zhou, B., *et al.*, LC-MS-based metabolomics. *Mol. Biosyst.*, **8(2)**, 470-481 (2012).
20. Theodoridis, G., *et al.*, LC-MS-based methodology for global metabolite profiling in metabolomics/metabolomics. *TrAC Trends Anal. Chem.*, **27(3)**, 251-260 (2008).
21. Ivanisevic, J., and Want, E.J., From samples to insights into metabolism: Uncovering biologically relevant information in LC-HRMS metabolomics data. *Metabolites*, **9(12)**, 308 (2019).
22. Sarvin, B., *et al.*, Fast and sensitive flow-injection mass spectrometry metabolomics by analyzing sample-specific ion distributions. *Nature Communications*, **11(1)**, 3186 (2020).

Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

Technical Assistance

Visit the tech service page at SigmaAldrich.com/techservice.

Terms and Conditions of Sale

Warranty, use restrictions, and other conditions of sale may be found at SigmaAldrich.com/terms.

Contact Information

For the location of the office nearest you, go to SigmaAldrich.com/offices.

The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

Merck and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.
Document SBR00052 Rev 09/22

